StonvexLoading…
StonvexStonvexStonvexCore line items from GEN's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.
| Metric | Q1 2026 2026-01-02 | Q4 2025 2025-10-03 | Q3 2025 2025-07-04 | Annual 2025 2025-03-28 |
|---|---|---|---|---|
Revenue | $3.72B | $2.48B | $1.26B | $3.94B |
Operating Income | $1.32B | $884.00M | $446.00M | $1.61B |
Net Income | $461.00M | $269.00M | $135.00M | $643.00M |
EPS (Diluted) | $0.74 | $0.43 | $0.22 | $1.03 |
Total Assets | $15.83B | $16.05B | $16.36B | $15.49B |
Total Liabilities | $13.50B | $13.59B | $13.99B | $13.23B |
Cash & Equivalents | $619.00M | $701.00M | $828.00M | $1.01B |
Free Cash Flow OCF − CapEx | $1.05B | $512.00M | $405.00M | $1.21B |
Shares Outstanding | 606.00M | 617.00M | 616.00M | 617.00M |